Current therapy for bronchiolitis
- Department of Paediatric Respiratory Medicine/Paediatric Cystic Fibrosis Centre, Children's Hospital for Wales, Cardiff, UK
- Correspondence to Iolo Doull, Department of Paediatric Respiratory Medicine/Paediatric Cystic Fibrosis Centre, Children's Hospital for Wales, Cardiff CF14 4XW, UK
Contributors PN and ID contributed equally to the design and writing of the manuscript.
- Received 20 December 2011
- Accepted 16 May 2012
- Published Online First 25 June 2012
Bronchiolitis is a common, self-limiting, seasonal viral respiratory tract infection in infancy accounting for the majority of hospital admissions in this age group. Supportive care is the mainstay of treatment, concentrating on fluid replacement, gentle suctioning of nasal secretions, prone position (if in hospital), oxygen therapy and respiratory support if necessary. There is a long history of pharmacological agents offering no benefit in acute bronchiolitis. More recently, nebulised epinephrine has been demonstrated to offer short term benefits, while two stratagems have shown promise in decreasing risk of hospitalisation and length of hospital stay. The combination of oral dexamethasone with nebulised epinephrine potentially decreases the need for hospitalisation, while nebulised 3% hypertonic saline mixed with a bronchodilator decreases the length of hospitalisation. Although both stratagems appear safe and well tolerated, their role in clinical practice remains unclear.
Competing interests None.
Provenance and peer review Commissioned; externally peer reviewed.